If we are talking pancreatic specifically Marker only has data on, IIRC, 13 patients. It's just not enough to entice big pharma, IMO. Again, that's if Marker even wants a partner. If they think they can get enough grant money coming in to run this, what should be tiny and inexpensive, trial then I think it makes sense to wait. If they can expand on the BCM pancreatic data they have a better shot at getting more attention from a potential BP partner.
News 
Market Data 
Discover 
